Welcome to the MAGRIT study site!

MAGRIT is a large Phase III clinical study that will evaluate the use of ASCI* (or Antigen-Specific Cancer Immunotherapeutics) in the treatment of Non-Small Cell Lung Cancer (NSCLC) patients, after operation of their tumor.

MAGRIT is designed to determine how safe ASCI* are and how good they work.

After 27 months of treatment with either ASCI* or a placebo (a dummy treatment), each patient will be followed for in total 10 years.

If you are interested, follow next 3 steps:

• Be fully informed about all aspects of the MAGRIT study
• Check if you are suitable for this study.
• Find a study center close to where you live and contact that hospital for a first discussion on the study and your potential participation in it.

You may contact GSK at any time for assistance and information.

Thank you for your interest in the MAGRIT study.